OneSource Specialty Pharma, the Bengaluru-based contract development and manufacturing organization (CDMO) swung to a net profit of Rs 44.9 crore in the September quarter, reversing a loss a year earlier, led by revenue and margin expansion.
The CDMO reported consolidated revenue of Rs 375.8 crore, up 12% year-on-year, while EBITDA surged 37% to Rs 106.5 crore, lifting margins by 506 basis points to 28%. Adjusted earnings per share stood at Rs 3.90, signaling a sharp turnaround in profitability.
Chief Executive Officer Neeraj Sharma said the performance was driven by master service agreements and sales from the company’s IP-led base business.
“We are accelerating drug-device combination (DDC) capacity additions to support upcoming customer launches and raising our FY28 revenue outlook to over $500 million,” Sharma said.
OneSource is betting on the launch of weight loss GLP-1 generic launches to boost its revenue.
The outlook upgrade comes on the back of strategic expansion plans, including a proposed multi-dose fill-finish site in Europe and an integrated carbapenem facility in India.
The recently announced acquisition of Poland and Brooks contributed $29 million in revenue and $11 million in EBITDA during the first half, with margins of 38%, highlighting strong integration prospects.
OneSource, which operates five globally approved manufacturing facilities, continues to position itself as a pure-play CDMO focused on complex pharmaceutical products such as biologics, sterile injectables, and drug-device combinations.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
